دورية أكاديمية
A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma:Results from DARENCA study 2
| العنوان: | A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma:Results from DARENCA study 2 |
|---|---|
| المؤلفون: | Soerensen, Anne V, Geertsen, Poul F, Christensen, Ib J, Hermann, Gregers G, Jensen, Niels V, Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede |
| المصدر: | Soerensen , A V , Geertsen , P F , Christensen , I J , Hermann , G G , Jensen , N V , Fode , K , Petersen , A , Sandin , R & Donskov , F 2015 , ' A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma : Results from DARENCA study 2 ' , Acta Oncologica . https://doi.org/10.3109/0284186X.2015.1091499Test |
| سنة النشر: | 2015 |
| المجموعة: | Aarhus University: Research |
| الوصف: | BACKGROUND: Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers in the early treatment phase is unclear. MATERIAL AND METHODS: In a complete national cohort of mRCC patients receiving first-line tyrosine kinase inhibitors (TKI) or interleukin-2 based immunotherapy (IT) from 2006 to 2010, overall survival (OS) was analysed for baseline International mRCC Database Consortium (IMDC) classification factors and on-treatment time-dependent biomarkers obtained day 1 each cycle week 4-12 after treatment initiation with multivariate analysis and bootstrap validation. RESULTS: A total of 735 patients received first-line TKI (59%) or IT (41%). Median OS was overall 14.0 months and 33.4, 18.5, and 5.8 months for baseline IMDC favourable, intermediate, and poor risk groups, respectively (p < 0.0001). Systolic blood pressure ≥140 mmHg, neutrophils < lower level of normal (LLN), platelets < LLN, sodium ≥ LLN, and LDH ≤1.5 times upper level of normal after treatment initiation were significantly associated with favourable OS independent of baseline IMDC risk group in multivariate analyses stratified for TKI and IT (p ≤ 0.04). Concordance (C)-index for IMDC classification alone was 0.625 (95% CI 0.59-0.66) and combined with the five-factor biomarker profile 0.683 (95% CI 0.64-0.72). For patients with good (3-5 factors) and poor (0-2 factors) biomarker profile median OS were 23.5 and 9.6 months, respectively (p < 0.0001). Adding the five-factor biomarker profile significantly improved prognostication in IMDC intermediate (25.7 vs. 12.0 months, p < 0.0001) and poor (12.8 vs. 6.4 months, p < 0.0001) risk groups. A trend was seen in IMDC favourable risk group (38.9 vs. 28.7 months, p = 0.112). CONCLUSION: On-treatment hypertension, neutropenia, thrombocytopenia, LDH below 1.5 times upper level of normal, and normal sodium, obtained week 4-12 of treatment, are independent biomarkers of ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.3109/0284186X.2015.1091499 |
| الإتاحة: | https://doi.org/10.3109/0284186X.2015.1091499Test https://pure.au.dk/portal/da/publications/a-fivefactor-biomarker-profile-obtained-week-412-of-treatment-for-improved-prognostication-in-metastatic-renal-cell-carcinomaTest(40c6d83f-52e1-4c01-b0a4-959af55c7b19).html |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.B5CB1DB6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3109/0284186X.2015.1091499 |
|---|